Anacor Pharmaceuticals Inc (ANAC.OQ)
|Market Cap (Mil.):||$1,186.80|
|Shares Outstanding (Mil.):||42.00|
- Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail.
July 8 - Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the toenail.
July 8 - Anacor Pharmaceutical Inc said the U.S. Food and Drug Administration approved its treatment for a fungal infection of the nail, sending the drug developer's shares up about 9 percent in premarket trade.
|Astellas Pharma Inc (4503.T)||¥1,598||+20.50|
|DAIICHI SANKYO COMPANY, LIMITED (4568.T)||¥1,678||+43.00|
|Dr. Reddy's Laboratories Limited (REDY.NS)||Rs3,057.65||+19.90|
|Pfizer Inc. (PFE.N)||$29.11||+0.51|
|Johnson & Johnson (JNJ.N)||$103.13||+0.50|
|Novartis AG (NOVN.VX)||CHF85.75||+0.35|
|Merck & Co., Inc. (MRK.N)||$57.61||+0.98|
|Abbott Laboratories (ABT.N)||$42.46||+0.03|
|Sanofi SA (SASY.PA)||€84.60||-0.30|
|AstraZeneca plc (AZN.L)||4,327.50p||-7.00|
Earnings vs. Estimates
Analyst Research Reports
Provider: New Constructs, LLC
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ANACOR PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: Thomson Reuters Stock Report
Trading Report for (ANAC). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.